

## Angélique Gougelet, PhD

Born on March 13<sup>th</sup>, 1980 at Châtenay-Malabry, France

Centre de Recherche des Cordeliers-Umrs1138

15 rue de l'école de médecine

75006 Paris

01 44 27 60 36

[angelique.gougelet@inserm.fr](mailto:angelique.gougelet@inserm.fr)

<https://www.crcordeliers.fr/equipes/oncogenic-functions-of-b-catenin-signaling-in-the-liver/>

---

### ACTUAL POSITION

Co-director of the Team “Oncogenic functions of the beta-catenin in the liver” directed by S. Colnot, “Chargé de Recherche Classe Normale” since october 2015

---

### EDUCATION

10/2010-10/2015: Post-doctoral Fellow, INSERM U1016, Institut Cochin, Paris, France

05/2007-07/2010: Post-doctoral Fellow, INSERM U590, Centre Léon Bérard, Lyon, France

01/2004-01/2007: PhD in Biology, Paris XI University, Châtenay-Malabry, France

---

### TRAINING & TEACHING

- Internships of 17 students, 2 PhD students
- Teaching in L3 Pro « Microbiologie Industrielle et Biotechnologies » and M2 MIAC (2011-now) for Université Paris Cité, and M1 “Magistère Européen de Génétique” (2019-now) for Université Paris Cité, and « DIU Médecine moléculaire en cancérologie » (2022) for Université Paris Saclay/SIRIC CARPEM
- Organizer of workshops for the “Fête de la Science” (2016-2018, 2021, 2022) and for young students from “Envol” association (2016-now)

---

### SCIENTIFIC EXPERTISE

- Editorial member of the “World Journal of Hepatology” Journal since April 2018
- Reviewing of more than 100 international manuscripts (*Gut, Liver International, Journal of Hepatology, Hepatology, Journal of Clinical Investigation, JHep Report, International Journal of Hepatology...*)
- Member of the organizing committee for seminars in Centre de Recherche des Cordeliers
- “Rang B” representative in UFR927 council
- Member of the “bureau des personnels” in UFR927
- Member of the selection committee for abstracts during EASL meeting 2023-2025
- Expert for grants from AFEF, National Science Centre Poland, Ligue Nationale contre le Cancer, Telethon Grant in Italy and a grant for the Israel Science Foundation
- Reporter of four theses, eight “Comité de suivi de thèse”, one « Maitre de Conférences » recruitment examination
- Member of the selection committee for abstracts during AFEF meeting 2020
- Representative of the “Chargé de Recherche” in Cochin Institute
- Speaker in 20 meetings, invited in 6

---

### FUNDINGS

- PLBIO21 « Liver resident macrophages: key actors in the pathogenesis of hepatocellular carcinoma” (2022-2025)
- ANR JCJC «  $\beta$ -catenin-mediated epigenetic control of the imprinted DLK1/Dio3 locus in liver” (2018-2021)
- AAP *Association Française d'Etude du Foie* 2018

---

### PRIZE AND DISTINCTIONS

- APEMM Prize for the best manuscript in 2015
- Young investigator Bursaries in EASL 2013 and EASL HCC summit 2014
- Young researcher Bursaries in AFEF 2013
- Prize of the best talk in the Wnt meeting 2010

## PUBLICATIONS

**ORCID number:** 0000-0001-7464-9804,  
**Scopus Author ID:** 8737049800  
 16 international manuscripts, 11 international  
 reviews, 2 book chapters

Web of Science Core Collection metrics

|   |  |
|---|--|
| <b>12</b><br><small>H-Index</small>             | <b>28</b><br><small>Publications in<br/>Web of Science</small> |
| <b>790</b><br><small>Sum of Times Cited</small> | <b>741</b><br><small>Citing Articles</small>                   |

| Google Scholar | Toutes | Depuis 2017 |
|----------------|--------|-------------|
| Citations      | 1187   | 544         |
| indice h       | 15     | 11          |
| indice i10     | 18     | 14          |

### *Main international manuscripts*

Loesch R, Caruso S, Paradis V, Godard C, **Gougelet A**, Renault G, Picard S, Tanaka I, Renoux-Martin Y, Perret C, Taketo MM, Zucman-Rossi J, Colnot S. Deleting the  $\beta$ -catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. *J Hepatol.* 2022 Mar 4:S0168-8278(22)00130-1. doi: 10.1016/j.jhep.2022.02.023.

M. Cadoux, S. Caruso, S. Pham, **A. Gougelet**, ... and J-P. Couty. NKG2D ligands expression is down regulated by beta-catenin signalling and correlates with HCC aggressiveness in mice and human. **J.Hepatol.** 2021 Jan 20:S0168-8278(21)00028-3. doi: 10.1016/j.jhep.2021.01.017.

**A. Gougelet\***, C. Sartor\*, N. Senni\*, ... and S.Colnot. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography **Gastroenterology.** 2019; 157 (3): 807-822. doi: 10.1053/j.gastro.2019.05.069.

C. Sartor, ..., **A. Gougelet\*** and S. Colnot\*. The concomitant loss of APC and HNF4 $\alpha$  in adult hepatocytes does not contribute to hepatocarcinogenesis driven by  $\beta$ -catenin activation. **Liver Int.** 2019; 39 (4): 727-739. doi: 10.1111/liv.14068\* AG and SC contributed equally to this work

Senni N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, Sartor C, Lagoutte I, **Gougelet A**, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P.  $\beta$ -catenin-activated hepatocellular carcinomas are addicted to fatty acids. **Gut.** 2018; 68 (2): 322-334. doi: 10.1136/gutjnl-2017-315448.

**A. Gougelet**, C. Sartor, L. Bachelot, *et al.* Antitumor activity of an inhibitor of miR-34a in liver cancer mutated for  $\beta$ -catenin. **Gut.** 2016; 65:6 1024-1034. doi: 10.1136/gutjnl-2014-308969.

**A. Gougelet**, C.Torre, P.Veber, *et al.* T-cell factor 4 and  $\beta$ -catenin chromatin occupancies pattern zonal liver metabolism. **Hepatology.** 2014 Jun; 59(6): 2344-57. doi: 10.1002/hep.26924.

### *Main international reviews*

J. Sanceau and **Gougelet A.** Epigenetic mechanisms of liver tumor resistance to immunotherapy. **World J Hepatol.** 2021 Sep 27;13(9):979-1002. doi: 10.4254/wjh.v13.i9.979.

**Gougelet A**, Colnot S. Une Imagerie métabolique des cancers primitifs du foie basée sur leur addiction à la Choline permet de prédire leur oncogénotype, et de proposer une piste thérapeutique. **Med Sci (Paris).** 2020 Apr;36(4):322-326. doi: 10.1051/medsci/2020051.

**A. Gougelet** and C. Desbois-Mouthon. Non-coding RNAs Open a New Chapter in Liver Cancer Treatment. **Clin Res Hepatol Gastroenterol.** 2019, 43 (6): 630-637. 10.1016/j.clinre.2019.07.005

**A. Gougelet.** Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma? **Gut.** 2019; 68 (10): 1727-1728. doi: 10.1136/gutjnl-2019-319084.

Lechel A and **Gougelet A.** Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions? **Gut.** 2016 Mar 4. 65: (7) 1073-1074. doi: 10.1136/gutjnl-2016-311446.

### *Book chapter*

**Gougelet A**, Colnot S. Chapter 8: MicroRNAs linking cancer and inflammation: focus on liver cancer in the book “MicroRNAs: Key Regulators of Oncogenesis”, Springer. DOI: 10.1007/978-3-319-03725-7\_8

J. Sanceau and **Gougelet A.** Applications of Non-Coding RNAs in Liver Cancer Patients in the book “Clinical Applications of Non-Coding RNAs in Cancer” from Elsevier. DOI: 10.1016/B978-0-12-824550-7.00007-2